Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The IκB kinase (IKK) complex and the Nuclear factor kappa B (NF-κB) pathway components represent a fundamental signaling network that regulates the cellular response to inflammation, stress, and infection (Source: StatPearls, NBK557533). The IKK complex, primarily composed of the catalytic subunits IKKα (CHUK) and IKKβ (IKBKB) and the regulatory subunit NEMO (IKKγ), serves as the primary activator of the pathway by phosphorylating IκB inhibitory proteins (Source: UniProt, O14920). This phosphorylation triggers the ubiquitination and proteasomal degradation of IκB, thereby releasing NF-κB transcription factor dimers (such as p50/p65) to translocate from the cytoplasm to the nucleus (Source: PubMed, PMID: 11861295). Once in the nucleus, NF-κB binds to specific DNA sequences to induce the expression of genes involved in the innate and adaptive immune response, cell survival, and the production of pro-inflammatory cytokines like TNF-α and IL-6 (Source: PubMed, PMID: 15123778). Dysregulation of this pathway, particularly constitutive activation, is a hallmark of many human pathologies, including chronic inflammatory diseases (e.g., rheumatoid arthritis, IBD) and various malignancies where it promotes tumor cell proliferation and resistance to apoptosis (Source: Nature Reviews Drug Discovery, nrd1926). Therapeutic targeting of this pathway includes the use of proteasome inhibitors to prevent IκB degradation and direct IKK inhibitors, although the essential role of NF-κB in normal physiology often leads to significant safety concerns such as severe immunosuppression and toxicity (Source: PubMed, PMID: 24333740).
Inhibition of IκB kinase (IKK) activity, proteasomal inhibition preventing IκB degradation, blockade of NF-κB nuclear translocation, and inhibition of upstream pathway activators (Source: PubMed PMID: 16397573).
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on IκB kinase complex and Nuclear factor kappa B (NF-κB) pathway components (IKK/NF-κB).